The industry’s focus on living human beings and the strict standards it enforces provide unique considerations for business leaders. These characteristics make the industry an ideal place to foster innovation. They have resulted in major breakthroughs in agricultural yields, biofuels, and life-saving pharmaceuticals.
Biotech startups have a myriad of options when it comes to revenue generation strategies, with most opting for a technology-based partnership or an asset creation and out-licensing strategy. Technology-based partnerships can produce more revenue and lower risk to the financials, whereas assets creation and outlicensing strategies are able to yield much greater returns. A increasing number of biotechs in the research stage use the hybrid approach, which combines both strategies.
People who choose an approach to development that is oriented towards product can be successful commercially if they can get their pipeline up to the right stage and also attract a significant pharma partner or an investor with deep pockets. This could be expensive however, and the balance of opportunistic strategies to leverage outside resources while making the right research-based decisions regarding homegrown projects is essential.
The “platform” model is an alternative alternative to generate revenue. It’s a lower-cost method than the development-oriented model however, it comes with substantial risk. In this model, a biotech is the owner and develops its platform technology, before working with large pharma companies to create a portfolio drug discovery projects that focus on specific diseases (i.e., disease x in biology y). This is the approach that Advinus Therapeutics and a few others have adopted.
https://genotec-frankfurt.de/comparing-biotechnologically-engineered-nutritious-supplements/